Market Intelligence, Clinical Progress, and High-Purity Reagents for Hypertension, Edema, Bartter Syndrome, and Diuretic-Resistant Conditions.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NKCC2/SLC12A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Membrane Target | SLC12A1 Full-Length Membrane Protein (Custom Nanodisc / Detergent). Sequence Verified. High Purity (>95%). Endotoxin Controlled. | View SLC12A1 Products |
| Gene Delivery | SLC12A1 Lentivirus Premade Particles. Full-length ORF for stable cell lines. HEK293 Expressed. Sequence Verified. Endotoxin Controlled. | View SLC12A1 Products |
| Functional Cell Line | SLC12A1 Overexpression Stable Cell Line. High surface expression validated by Rubidium uptake. Native Glycosylation. | View SLC12A1 Products |
| Mutant Library | Bartter Syndrome Mutants (G741R, L472P, R302Q; and BARTS1 variants rs137853158, rs137853157, rs1552311). Sequence Verified ORFs for mechanism of resistance and functional rescue studies. | View SLC12A1 Products |
| Benchmark Ab | Anti-NKCC2 Extracellular Loop Antibody (Recombinant). Positive control for Western blot, flow cytometry, and expression validation. | View SLC12A1 Products |
| Validator | SLC12A1 siRNA Set (3 unique targets). For knockdown verification in native renal cell lines. Sequence Verified. | View SLC12A1 Products |
| Related Target A (Selectivity) | SLC12A2 (NKCC1). Widely expressed isoform; essential for selectivity counter-screening to avoid ototoxicity. | View SLC12A2 Products |
| Related Target B (Pathway) | SLC12A3 (NCC). Thiazide-sensitive cotransporter; same family off-target liability; synergy target for combination diuretic therapy. | View SLC12A3 Products |
| Related Target C (Functional Complex) | KCNJ1 (ROMK). Potassium channel partner in thick ascending limb functional complex; also a target for Bartter syndrome type II. | View KCNJ1 Products |
Critical Assay Challenges & TarMart Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Conformation Preservation (12-TM Transporter) | Lentivirus-mediated stable cell lines preserving native membrane topology and HEK293-specific glycosylation patterns. |
| Isoform Selectivity (NKCC2 vs NKCC1) | Human SLC12A1 and SLC12A2 ortholog stable cell lines available for parallel counter-screening (>95% sequence coverage). |
| Functional Ion Flux Validation | Rubidium Uptake Assay-Ready Lines with validated high surface expression and transport capacity; also compatible with FLIPR and patch-clamp. |
| Bartter Syndrome Mutation Modeling | Site-directed mutant ORFs (G741R, L472P, R302Q, and BARTS1 variants) – Sequence Verified, Endotoxin <1EU/μg. |
| Family Off-target Liability (SLC12 Family) | Access to SLC12A3, SLC12A4, SLC12A5 ortholog proteins for comprehensive counter-screening. |
| Lack of Controls | Benchmark antibodies targeting specific extracellular loops included. |
| False Positives | Validated siRNA included for specificity checks and endogenous knockdown. |
Live NKCC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for SLC12A1 (NKCC2) is evolving beyond traditional loop diuretics (furosemide, bumetanide) toward precision nephrology. While first-generation therapies dominate fluid overload and hypertension, their lack of selectivity for renal-specific NKCC2 over ubiquitous NKCC1 drives dose-limiting ototoxicity and systemic hypotension. The next wave of R&D targets: (1) kidney-selective inhibitors or targeted delivery systems sparing NKCC1-expressing tissues; (2) cryo-EM structure-based drug design (SBDD) for highly selective SLC inhibitors; (3) gene therapy and small-molecule chaperones for Bartter Syndrome Type I (loss-of-function mutations). Avoiding off-target NKCC1 inhibition remains the critical focus. Simultaneously, drug resistance mechanisms (e.g., specific SLC12A1 mutations) are being explored to overcome diuretic resistance in refractory hypertension and chronic kidney disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules (Loop Diuretics) | Sanofi, Novartis, Generic manufacturers | Heart Failure, Acute Edema | Selectivity Assay vs SLC12A2 (need parallel cell lines) |
| Next-gen Selective Inhibitor | Academic Consortia, Preclinical Biotech | Resistant Hypertension, Edema | Functional Rubidium Uptake in SLC12A1-expressing cells; NKCC2 vs NKCC1 counter-screening |
| Gene Therapy / Modulators | Rare Disease Biotechs, Academic labs | Bartter Syndrome Type I | Functional Rescue assays using Bartter mutant plasmids/lentivirus (G741R, L472P, R302Q, etc.) |
| Targeted Degraders (PROTACs) | Early Stage Innovators | Refractory Hypertension | Degradation Tracking requiring specific extracellular/intracellular antibodies |
| Targeted Delivery (ADC/Prodrug) | Emerging platforms | Chronic Kidney Disease, Diuretic Resistance | Internalization & Trafficking Validation (cell-based) |
Bartter Syndrome Mutations and Functional Assays
Loss-of-function mutations in SLC12A1 cause Bartter Syndrome Type I (autosomal recessive). Key mutations reported in patients include G741R, L472P, R302Q, and dbSNP variants rs137853158, rs137853157, rs1552311 (derived from UniProt Q13621). These mutations impair NKCC2 trafficking, membrane expression, or ion transport activity. TarMart offers customized lentivirus and plasmid constructs expressing these mutants for:
- Membrane localization rescue screens (e.g., surface biotinylation, confocal microscopy)
- Functional recovery assays (Rubidium uptake or patch-clamp)
- High-throughput screening for small-molecule chaperones or gene therapy vectors
Accurate modeling of these mutations is essential for developing therapies for this rare but severe nephropathy.